Pelacarsen missed its primary endpoint in the Lp(a)HORIZON trial. Here’s what’s actually known, what two doctors think happened, and why I’m putting my own effort back into LDL and ApoB instead of waiting on an Lp(a) drug.
I paid Lilly’s self-pay price for Zepbound for months, and retatrutide has no announced price yet, so here is what Lilly’s own price ladders imply.
CagriSema has no announced brand name as of September 4, 2026. Novo Nordisk owns eleven invented names it could use, and it bought the matching web address for only six of them.
Retatrutide still has no brand name. But Lilly filed 20 new trademarks in a month and 19 are built on reta, from VYNRETA to YEZRETA. Here is the whole list, which domains Lilly quietly bought first, and what happened the last time it did this.
Retatrutide beat Zepbound’s numbers in its own trials, and it did not need its top dose to do it. I take Zepbound, I lost about 170 pounds on it, and I am staying put.
My coronary calcium score is zero. What a zero doesn’t rule out, what a new NEJM study found about plaque without calcium, and whether the $2,000 AI heart scan (Cleerly or HeartFlow) is worth it at 53.
I do not take a statin. I got my ApoB to 59 with about 170 pounds of weight loss and a generic ezetimibe that runs me twenty dollars a month, so when a big statin trial reads out I have nothing invested in the answer. I have also written here about why most of the
Melanoma flips male after 50 and keeps climbing. Merck and Moderna announced a Phase 3 win with no efficacy numbers attached, so here is what is actually known about the drug, and what is worth knowing about your own skin.
I inject a drug made by a compounding pharmacy with a warning letter to its name. Reading that letter is what taught me how to buy every drug I take.
I’ve got severe big toe arthritis. The first real trial on big toe arthritis surgery beat waiting. My foot doctor still says I’m not a candidate yet.
